左心衰无创预后生物标志物对肺动脉高压生存的预测价值
该研究在2017例成人第1组肺动脉高压患者中评估ST2、Gal3和NT-proBNP与疾病严重程度及生存的关系。结果显示较高ST2和NT-proBNP与更高肺压、肺血管阻力及更低6分钟步行距离相关,且与死亡风险增加独立相关;将ST2加入包含NT-proBNP等预测因素的生存模型可显著改善模型拟合与预测能力。Gal3在PAH中无预测价值。
要点
- ST2和NT-proBNP是PAH较强的无创预后标志物,与疾病严重程度及死亡风险相关。
- Gal3虽在左心衰中有预后价值,但在PAH中未显示预测作用。
- 将ST2加入含NT-proBNP等预测因素的生存模型可显著提升预测能力。
核心结论
- ST2和NT-proBNP是PAH中强效的无创预后生物标志物,而Gal3在PAH中无预测价值。
- 将ST2加入生存模型可显著改善模型拟合与预测能力。
研究设计与样本
- 研究纳入2017例成人第1组肺动脉高压患者,获取生物标志物测量值与临床数据。
- 采用多变量回归模型分析生物标志物水平与临床变量及生存时间的关联。
- 使用似然比检验和Akaike信息准则比较生存模型。
主要发现
- 较高ST2和NT-proBNP与更高肺动脉压、更高肺血管阻力及更低6分钟步行距离相关。
- 较高ST2水平与死亡风险增加相关(HR 2.79;95%CI 2.21-3.53;P < .001)。
- 较高NT-proBNP水平与死亡风险增加相关(HR 1.84;95%CI 1.62-2.10;P < .001)。
- 将ST2加入包含NT-proBNP等其他生存预测因素的模型,显著改善模型拟合与预测能力。
- Gal3在PAH中未显示预测价值。
临床怎么用
- 在PAH患者中可考虑检测ST2和NT-proBNP用于无创预后风险评估。
- 将ST2与NT-proBNP等指标联合纳入生存模型可能提升风险分层能力。
- Gal3不推荐用于PAH的预后评估。
局限性
- 研究为观察性设计,需未来研究开发多标志物检测以改善PAH无创风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three biomarkers, soluble suppression of tumorigenicity 2 (ST2), galectin 3 (Gal3), and N-terminal brain natriuretic peptide prohormone (NT-proBNP), are approved for noninvasive risk assessment in left-sided heart failure, and small observational studies have shown their prognostic usefulness in heterogeneous pulmonary hypertension cohorts. We examined associations between these biomarkers and disease severity and survival in a large cohort of patients with pulmonary arterial hypertension (PAH) (ie, group 1 pulmonary hypertension). We hypothesized that additive use of biomarkers in combination would improve the prognostic value of survival models. METHODS: Biomarker measurements and clinical data were obtained from 2,017 adults with group 1 PAH. Associations among biomarker levels and clinical variables, including survival times, were examined with multivariable regression models. Likelihood ratio tests and the Akaike information criterion were used to compare survival models. RESULTS: Higher ST2 and NT-proBNP were associated with higher pulmonary pressures and vascular resistance and lower 6-min walk distance. Higher ST2 and NT-proBNP levels were associated with increased risk of death (hazard ratios: 2.79; 95% CI, 2.21-3.53; P < .001 and 1.84; 95% CI, 1.62-2.10; P < .001, respectively). The addition of ST2 to survival models composed of other predictors of survival, including NT-proBNP, significantly improved model fit and predictive capacity. CONCLUSIONS: ST2 and NT-proBNP are strong, noninvasive prognostic biomarkers in PAH. Despite its prognostic value in left-sided heart failure, Gal3 was not predictive in PAH. Adding ST2 to survival models significantly improves model predictive capacity. Future studies are needed to develop multimarker assays that improve noninvasive risk stratification in PAH.
引用
- Simpson CE, Damico RL, Hassoun PM, et al. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest. 2020. PMID: 31987881. doi:10.1016/j.chest.2019.12.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。